

**C2 Antibody (N-term) Blocking peptide**  
**Synthetic peptide**  
**Catalog # BP10662a****Specification**

---

**C2 Antibody (N-term) Blocking peptide - Product Information**

Primary Accession [P06681](#)

**C2 Antibody (N-term) Blocking peptide - Additional Information**

**Gene ID** 717

**Other Names**

Complement C2, C3/C5 convertase, Complement C2b fragment, Complement C2a fragment, C2

**Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

**Storage**

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

**Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

**C2 Antibody (N-term) Blocking peptide - Protein Information**

**Name** C2

**Function**

Component C2 which is part of the classical pathway of the complement system is cleaved by activated factor C1 into two fragments: C2b and C2a. C2a, a serine protease, then combines with complement factor C4b to generate the C3 or C5 convertase.

**Cellular Location**

Secreted.

**C2 Antibody (N-term) Blocking peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)

**C2 Antibody (N-term) Blocking peptide - Images****C2 Antibody (N-term) Blocking peptide - Background**

Component C2 is a serum glycoprotein that functions as part of the classical pathway of the complement system. Activated C1 cleaves C2 into C2a and C2b. The serine proteinase C2a then combines with complement factor 4b to create the C3 or C5 convertase. Deficiency of C2 has been reported to be associated with certain autoimmune diseases and SNPs in this gene have been associated with altered susceptibility to age-related macular degeneration. This gene localizes within the class III region of the MHC on the short arm of chromosome 6. Alternative splicing results in multiple transcript variants encoding distinct isoforms. Additional transcript variants have been described in publications but their full-length sequence has not been determined.

#### **C2 Antibody (N-term) Blocking peptide - References**

Hu, M., et al. Pharmacogenet. Genomics 20(10):634-637(2010) Bailey, S.D., et al. Diabetes Care 33(10):2250-2253(2010) Liu, X., et al. Retina (Philadelphia, Pa.) 30(8):1177-1184(2010) Han, S., et al. Hum. Immunol. 71(7):727-730(2010) Ishii, Y., et al. J. Immunol. 151(1):170-174(1993)